Cell
Volume 180, Issue 6, 19 March 2020, Pages 1067-1080.e16
Journal home page for Cell

Article
Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism

https://doi.org/10.1016/j.cell.2020.02.035Get rights and content
Under an Elsevier user license
open archive

Highlights

  • PA is reduced in MS patients, particularly early after disease manifestation

  • PA reduction is associated with an altered gut microbiome composition

  • After 14 days of PA supplementation, Treg cell/TH17 imbalance was restored

  • Longitudinal PA supplementation might have clinical implications

Summary

Short-chain fatty acids are processed from indigestible dietary fibers by gut bacteria and have immunomodulatory properties. Here, we investigate propionic acid (PA) in multiple sclerosis (MS), an autoimmune and neurodegenerative disease. Serum and feces of subjects with MS exhibited significantly reduced PA amounts compared with controls, particularly after the first relapse. In a proof-of-concept study, we supplemented PA to therapy-naive MS patients and as an add-on to MS immunotherapy. After 2 weeks of PA intake, we observed a significant and sustained increase of functionally competent regulatory T (Treg) cells, whereas Th1 and Th17 cells decreased significantly. Post-hoc analyses revealed a reduced annual relapse rate, disability stabilization, and reduced brain atrophy after 3 years of PA intake. Functional microbiome analysis revealed increased expression of Treg-cell-inducing genes in the intestine after PA intake. Furthermore, PA normalized Treg cell mitochondrial function and morphology in MS. Our findings suggest that PA can serve as a potent immunomodulatory supplement to MS drugs.

Keywords

autoimmune diseases
multiple sclerosis
propionic acid
immune modulation
regulatory T cells
microbiome
neuroregeneration

Cited by (0)

25

These authors contributed equally

26

Senior author

27

Lead Contact